Ever wondered what makes CSI Singapore stand out as a leading cancer research institute? Find out by watching the latest edition of our CSI Singapore Corporate Video below! 👇 👨🔬 👩🔬 🔬 Please like and re-post! #csisingapore #cancerawareness #cancerresearch #cancerresearchinstitute #cancereducation
Cancer Science Institute of Singapore
Research Services
To better understand the causes of human cancer across Asia, thereby improve its detection, treatment and prevention.
About us
The CSI’s mission is to better understand the causes of human cancer across Asia, and thereby improve its detection, treatment and prevention for the benefit of patients. Our purpose-built research institute is one of five core-funded Research Centres of Excellence established by the Government of Singapore. Our outstanding researchers and excellent facilities create an energetic environment for ground-breaking science and world-class training. We are hosted by the National University of Singapore, a globally leading research university, empowering multidisciplinary research that spans cutting-edge approaches from the biological, computational, physiochemical and engineering sciences. Our location adjacent to the National University Hospital enables strong synergies with clinicians for fundamental and translational investigation. We are internationally recognized for our innovative achievements in studying the biology of cancers prevalent in Asia, and taking new methods for their treatment from the laboratory to the clinic. Our local and global partnerships mean we work with leading minds from multiple scientific and clinical disciplines from Singapore, the USA and Europe, both within academia and in industry.
- Website
-
https://linktr.ee/csi_singapore
External link for Cancer Science Institute of Singapore
- Industry
- Research Services
- Company size
- 201-500 employees
- Headquarters
- Singapore
- Type
- Educational
Locations
-
Primary
Get directions
14 Medical Dr
12-00
Singapore, 117599, SG
Employees at Cancer Science Institute of Singapore
Updates
-
Congratulations, Dennis Kappei and team for their new publication and their excellent work with EMBO!
Principal Investigator, Cancer Science Institute of Singapore Assistant Professor, National University of Singapore
EMBO has truly been the lucky charm for our team in 2024. First, we started the year as new members of the EMBO Global Investigator Network, which has been a wonderful way to connect to an amazing, wholesome community back in Europe. Second, we had the pleasure of organising the EMBO workshop "Chromatin Biology in Cancer" in April 2024 in Singapore. And to top it all, we just published our most recent work led by Grishma Rane in The EMBO Journal describing ZBTB48 as a priming factor for the adaptive immunity gene expression program. Grishma Rane together with Arne Jahn had previously identified ZBTB48 as a protein that directly binds to telomeres and limits their length, but also that ZBTB48 moonlights as a transcription factor (https://lnkd.in/gwzaujsA). Emerging from two undergraduate (at the time) internships with Julia Hansen and Ieva Norvaišaitė we took a closer look at how exactly ZBTB48 acts as a transcription factor. While revisiting prior ChIP-seq data we realised that we had overlooked a particularly exciting target gene, CIITA, because it is not expressed in non-immune cells. CIITA expression depends on 3 promoters and ZBTB48 sits right on top of the B-cell-specific promoter pIII. We biochemically mapped the binding sites and ZBTB48 binds directly to the two critical activating elements, ARE1/2. A corresponding co-crystal structure (with Fudong Li; University of Science and Technology of China) revealed involvement of ZnF10 & ZnF11 with the former dispensable for ZBTB48's telomeric function (--> separation-of-function). To test a functional impact, we induced CIITA/MHCII expression by IFNgamma treatment. In contrast to WT cells, ZBTB48 KO cells had strongly reduced CIITA & MHCII mRNA and protein levels. And excitingly, this also held true in an in-house established Zbtb48 KO mouse model (thank you Motomi Osato) with a near complete loss of MHC II surface expression in pre-B cells. Finally, we wanted to understand how ZBTB48 regulates CIITA (and other genes) and through epigenomics analyses came to the conclusion that ZBTB48 is a priming factor acting as a molecular on-off-switch while other TFs fine-tune how much mRNA is produced. We are very excited about extending this work, but for now we are just looking forward to carrying this happy moment into the end-of-year-celebrations. Thanks to the rest of the team that supported Grishma Rane in leading the charge, including Vivian Kuan, Michelle Mok, Vartika Khanchandani, Julia Hansen, Ieva Norvaišaitė, Naasyidah Zulkaflee, Wai Khang Yong, Arne Jahn, Vineeth T M, PhD and Motomi Osato (among those on LinkedIn). And as always we are blessed with a fantastic scientific environment at the Cancer Science Institute of Singapore, NUS Centre for Cancer Research (N2CR) & NUS Yong Loo Lin School of Medicine as well as our collaborators at Universitätsklinikum Carl Gustav Carus Dresden and University of Science and Technology of China.
-
Today, CSI Singapore hosted an in-person CSI Seminar Series with speaker - Prof. Ernesto Guccione, from Centre for OncoGenomics and Innovative Therapeutics, Mount Sinai. He spoke on the topic “Precision Medicine in Solid Tumors: New Tools and (some) New Ideas”. Mount Sinai Health System
-
-
Save the Date for #FCS2025! We will see everyone again from 5-7 Nov 2025. Mark your calendars! #savethedate #FCS2024 #cancereducation #cancerresearch #cancerawareness #cancer #conference2024 #research #internationalconference #CancerConference . . Duke-NUS Medical School Institute of Molecular and Cell Biology (IMCB) A*STAR Genome Institute of Singapore (A*STAR GIS) National Cancer Centre Singapore National University Cancer Institute, Singapore @NTU Lee Kong Chian School of Medicine Nanyang Technological University Singapore NUS Yong Loo Lin School of Medicine American Association for Cancer Research
-
-
The Frontiers in Cancer Science (FCS) 2024 conference took place from November 13-15, 2024, at The Matrix, Biopolis, Singapore. We trust that all delegates had an exceptional time exchanging ideas and insights with both peers and speakers. A heartfelt thank you to our official Conference Partner, the American Association for Cancer Research (AACR), for their support and for the enriching FCS-AACR Education Sessions. We would also like to express our gratitude to our sponsors for their continued support of the conference. #FCS2024 #cancereducation #cancerresearch #cancerawareness #cancer #conference2024 #research #internationalconference #CancerConference . . Duke-NUS Medical School Institute of Molecular and Cell Biology (IMCB) A*STAR Genome Institute of Singapore (A*STAR GIS) National Cancer Centre Singapore National University Cancer Institute, Singapore @NTU Lee Kong Chian School of Medicine Nanyang Technological University Singapore NUS Yong Loo Lin School of Medicine American Association for Cancer Research
-
-
-
-
-
+3
-
-
Our heartiest congratulations to the top 4 Poster Presenters of FCS 2024. Of the many outstanding posters we have received, their excellent presentations have won them some exciting prizes! 3rd and 4th place winners walk away with Amazon e-gift cards while the Top 2 have won themselves the prestigious AACR Travel Award to facilitate their attendance at AACR 2025. #FCS2024 #aacreducationsession #cancereducation #cancerresearch #cancercommunity #cancerawareness #cancerawareness #cancerresearchinstitute #aacr Duke-NUS Medical School National Cancer Centre Singapore National University Cancer Institute, Singapore NUS Yong Loo Lin School of Medicine American Association for Cancer Research
-
-
Warm congratulations to the 10 recipients of the 'Outstanding FCS Abstract Travel Award' for #FCS2024! Their travel and expenses to attend and present at #FCS2024 were fully covered. We hope to inspire more global abstract submissions in the future with this initiative. #FCS2024 #aacreducationsession #cancereducation #cancerresearch #cancercommunity #cancerawareness #cancerawareness #cancerresearchinstitute #aacr @dukenus @nationalcancercentresg @ncis.nuhs @ntu_lkcmedicine @nusmedicine @theaacr
-
-
-
-
-
+5
-
-
Cancer Science Institute of Singapore reposted this
A new research has revealed that nano-sized particles released by cells such as red blood cells, could be repurposed to function as drug delivery platforms to carry antisense oligonucleotide (ASO) molecules targeting cancer cells in the lungs, thereby suppressing cancer progression. This study conducted by the NUS Yong Loo Lin School of Medicine, in collaboration with the Cancer Science Institute of Singapore (CSI), A*STAR Genome Institute of Singapore (A*STAR GIS), National Cancer Centre Singapore (NCCS), and Duke-NUS Medical School, was published in eBioMedicine (https://lnkd.in/dBGtZ6-Q). Associate Professor Wai Leong Tam, Deputy Executive Director of A*STAR GIS, and co-corresponding author of the study, said, “The innovative use of extracellular vesicles as a delivery vehicle for nucleic acid therapeutics added a potentially powerful treatment modality for treating malignancies. The ability to precisely eliminate mutant EGFR cancer cells while sparing normal tissues will enable customised treatment for individual patients. This is a significant step towards addressing cancer drug resistance and advancing the application of personalised cancer medicine.” Read more at https://lnkd.in/gh_DfAf4
Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer
sciencedirect.com
-
#FCS2024 is now LIVE!! Starting today till Fri, 15 Nov, look forward to insightful and groundbreaking talks from our esteemed speaker panel. Check out CSI Singapore's IG Stories to stay updated on the exciting line-up. Come on down & register on-site 😊
-
-
The inaugural “Diana Koh Breakthroughs in Cancer Learning Series” took place on 4 May 2024 with Prof. Ashok Venkitaraman and Asst. Prof. Anand Jeyasekharan as esteemed speakers. We are delighted to share the recording from the learning series with everyone, to find out about the recent developments in cancer research and the prize presentation of the winners of the 'Diana Koh Young Innovator Prize' and the 'Diana Koh Young Innovator Grant'. https://lnkd.in/gn3P6RZQ Click on the above link to view the recording on the CSI website. Jointly supported by CSI Singapore, NUS Medicine and NUS Centre for Cancer Research (N2CR). NCIS NUHS NUS Centre for Cancer Research NUS Yong Loo Lin School of Medicine The Diana Koh Foundation, established in memory of the late Ms Diana Koh, made a generous gift of S$500,000 towards cancer research with the purpose to provide support to our junior researchers and graduate students working on cancer research to implement their own independent projects and explore research interests. It allows young researchers more directional control over their learning and provides tangible support to bring these ideas into fruition.
Diana Koh Fund - NUS CSI
https://csi.nus.edu.sg